Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25480250 | 1.00 | HRH3 (0.56) | HRH3KCNH2CYP2D6ALDH1A1SMN1; SMN2 | |
| SCHEMBL26494224 | 0.90 | HRH3 (0.55) | HRH3KCNH2CYP2D6ALDH1A1SMN1; SMN2 | |
| SCHEMBL25480271 | 0.90 | HRH3 (0.59) | HRH3KCNH2CYP2D6ALDH1A1SMN1; SMN2 | |
| SCHEMBL18745326 | 0.88 | HPGD (0.45) | HRH3ALDH1A1SMN1; SMN2HPGDTSHR | |
| SCHEMBL26790447 | 0.88 | HPGD (0.45) | HRH3ALDH1A1SMN1; SMN2HPGDTSHR | |
| SCHEMBL26046070 | 0.85 | ALDH1A1 (0.52) | HRH3ALDH1A1SMN1; SMN2HPGDTSHR | |
| SCHEMBL26170503 | 0.84 | HRH3 (0.49) | HRH3KCNH2CYP2D6ALDH1A1SMN1; SMN2 | |
| SCHEMBL25502011 | 0.83 | HSD11B1 (0.51) | HRH3ALDH1A1SMN1; SMN2HPGDHSD11B1 | |
| SCHEMBL25498343 | 0.82 | HRH3 (0.57) | HRH3KCNH2CYP2D6ALDH1A1SMN1; SMN2 | |
| SCHEMBL25489003 | 0.81 | HRH3 (0.54) | HRH3KCNH2CYP2D6ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | MDM2, XIAP, ADRM1 | HRH3 3926/4885KCNH2 4882/4885CYP2D6 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.